Ratings Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq Other stock markets 21:00:00 25/06/2024 BST			5-day change	1st Jan Change
2.09 ^USD	-4.13%		-23.16%	-30.10%

06-12	Transcript : Esperion Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:40 AM
05-22	Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.53 for the 2024 fiscal year.
The company has a low valuation given the cash flows generated by its activity.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ESPERION THERAPEUTICS, INC.	-30.10%	396M	D+
ELI LILLY AND COMPANY	+55.19%	815B	C+
NOVO NORDISK A/S	+47.26%	654B	B
JOHNSON & JOHNSON	-6.09%	354B	C+
MERCK & CO., INC.	+21.92%	337B	B-
ASTRAZENECA PLC	+18.40%	247B	B+
ROCHE HOLDING AG	+3.64%	229B	A+
NOVARTIS AG	+12.98%	219B	B-
AMGEN INC.	+10.86%	171B	C+
PFIZER, INC.	-2.78%	159B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes